chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site pain
Clinical narrative: Fever; Chills; Body aches; Pain at injection site; Headache; Nausea; Dizziness.; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP6955) via an unspecified route of administration in the left arm on 24Mar2021 at 11:00 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EL3247), via an unspecified route of administration in the left arm on 03Mar2021 at 11:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation and nitrofurantoin (MACROBID) on unknown date for unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 25Mar2021 at 01:30, the patient experienced fever, chills, body aches and pain at injection site with headache, nausea and dizziness. On 25Mar2021 at 01:30, the body temperature was reported as 101.3 (units unspecified). The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, general body pain, vaccination site pain, nausea, headache and dizziness was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Burning sensation, Paraesthesia
Clinical narrative: Tingling sensation on the left lower leg; Burning sensation on the left lower leg; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration on 22Mar2021 at 14:45 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none also the patient did not have any allergies to medications, food, or other products. Concomitant medications included vitamin (MANUFACTURER UNKNOWN) one a day from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 01:30, the patient experienced intermittent tingling and burning sensation on the left lower leg (outside of calf). The patient stated that it started approximately 36 hours after the shot. The tingling was intense enough to wake him up from sleep. This lasted about 36 hours. The tingling frequency and intensity slowly decreased over the 36 hour time period.  The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events tingling and burning sensation on the left lower leg were resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Paraesthesia
Clinical narrative: Numbness on the left cheek, nose; Numbness on the left cheek, nose and lip; Tingling; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: er2613), via an unspecified route of administration in the left arm on 24Mar2021 at 09:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Medical history included spice allergy (garlic). The patient did not take any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 10:00, the patient experienced tingling, followed by numbness on the left cheek, nose and lip. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events tingling, numbness and numbness lip was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Neck pain, Pain in extremity
Clinical narrative: Sore arm; Painful neck; This is a spontaneous report received from a contactable consumer. A male patient of unspecified age received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient was tested for COVID-19 or not. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021, the patient experienced sore arm and painful neck. No therapeutic measures were taken for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events sore arm and painful neck were recovering at the time of report.   No follow-up attempts are needed; information about batch/lot number cannot be obtained.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Myalgia, Pyrexia
Clinical narrative: Myalgia; Fever (Highest: 100F); Chills; Injection site pain; Headache; This is a spontaneous report from a contactable pharmacist, the patient. A 34-year-old male patient received his second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247), via an unspecified route of administration in the left arm on 23Mar2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported and Concomitant medications included Cetirizine (MANUFACTURER UNKNOWN) 10 mg once daily for an unspecified indication on an unknown date. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route on 04Mar2021, as single dose for COVID-19 immunisation. On 23Mar2021 at 15:00, the patient experienced fever (highest: 100F), chills, myalgia, injection site pain, headache. The patient received acetaminophen as treatment for the reported events. The patient events did not result in any of these doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever (highest: 100F), chills, myalgia, injection site pain, headache was recovered on an unknown date at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Myalgia; Fever (Highest: 100F); Chills; Injection site pain; Headache; This is a spontaneous report from a contactable pharmacist, the patient. A 34-year-old male patient received his second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247), via an unspecified route of administration in the left arm on 23Mar2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported and Concomitant medications included Cetirizine (MANUFACTURER UNKNOWN) 10 mg once daily for an unspecified indication on an unknown date. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route on 04Mar2021, as single dose for COVID-19 immunisation. On 23Mar2021 at 15:00, the patient experienced fever (highest: 100F), chills, myalgia, injection site pain, headache. The patient received acetaminophen as treatment for the reported events. The patient events did not result in any of these doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever (highest: 100F), chills, myalgia, injection site pain, headache was recovered on an unknown date at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Hyperhidrosis, Pyrexia
Clinical narrative: Sweat through about three changes of clothes.; Felt extremely feverish.; Had chills for the whole day; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 15:30 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. Medical history included allergy to dust mites. Concomitant medication included clindamycin/tretinoin (MANUFACTURER UNKNOWN) via topical route for unspecified indication and unspecified birth control medication (MANUFACTURER UNKNOWN); both started from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 03Mar2021 at 15:30 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 10:00, the patient felt extremely feverish and had chills for the whole day. The patient also experienced sweating through about three changes of clothes. The patient did not receive any treatment for events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The outcome of the events feverish, chills and sweating were resolved on an unspecified date in Mar2021.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: tested positive for Covid; This is a spontaneous report from a contactable consumer or other non hcp (patient herself). A 76-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 10Mar2021 (at the age of 76 years old) (Batch/Lot Number: EN6207; Expiration Date: 31Jul2021) as single dose for COVID-19 immunisation. Medical history included blood cholesterol, glaucoma. Concomitant medications included brimonidine tartrate, brinzolamide (SIMBRINZA) taken for glaucoma (been on it for about 6 years), latanoprost for glaucoma (Due to her insurance she was just changed to the generic. She had been taking brand name. She had been on it about the same about of time as Simbrinza), simvastatin taken for blood cholesterol (been on it between 8 to 10 years). It was reported that the patient received her first dose of the vaccine on 10Mar2021 and 12 days later tested positive for Covid on 22Mar2021. She received experimental infusion and they said she cannot receive another covid vaccine for 90 days. The doctor was not sure if she needed to restart the series. She asked if she would need to restart the series if she waits that long. She stated they recommend she get a blood test to see what the antibodies are after 90 days and she stated she will contact her HCP at that point. She had tested negative 5 days before, then tested positive. She got the infusion on 22Mar2021. They were very quick and on top of that. The patient has not received any other vaccines within 4 weeks prior vaccination. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on an unspecified date, sars-cov-2 test: positive on 22Mar2021. The outcome of the event was unknown.
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Mass excision
Clinical narrative: armpit pain; Lump; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received first single dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER2613) via an unspecified route of administration on the left arm on 17Mar2021 at 16:45 (at the age of 31-year-old) for COVID-19 immunisation. Medical history of patient was not reported. The patient's concomitant medication included prenatal vitamins (MANUFACTURER UNKNOWN). The patient had no known allergies reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medication within two weeks of vaccination. On 26MAR2021 at 07:45, the patient experienced armpit pain, and lump under left armpit. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures and treatment were not taken for the adverse event. The clinical outcome of the events armpit pain and lump was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Decreased appetite, Fatigue, Headache
Clinical narrative: Loss of appetite; Severe headache; Fever of 103.8; Left underarm lymph node swollen to the size of an egg; Joint pain; Injection site swell up to the sizeof my hand; Very fatigue; This is a spontaneous report received from a contactable consumer, the patient. A 53-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 22Mar2021 at 13:00 (at the age of 53-years-old) as a single dose, for COVID-19 immunisation. Medical history included asthma, high blood pressure, osteoarthritis and overweight. Concomitant medications included tiotropium bromide monohydrate (SPIRIVA RESPIMAT), budesonide, formoterol fumarate (SYMBICORT), meloxicam (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN); all for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 02Mar2021 at 15:00 (at the age of 53-year-old) as a single dose, for COVID-19 immunisation. The patient had a history of allergy to tree nuts. The patient did not receive any other vaccine in four weeks prior to COVID vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021 at 04:15, within 24 hours the patient had fever of 103.8 (unspecified units), left underarm lymph node swollen to the size of an egg, severe headache, joint pain, injection site swollen up to the size of hand, loss of appetite and had very fatigue. The patient reported that after 48 hours, body temperature went down to 101.6 (unspecified units) everything else the same. It was reported that on day 3, the body temperature of the patient had reduced to 100.5, appetite came back, still had some fatigue, joint pain reduced, lymph node still swollen and very painful, injection site still size of hand. The patient did not receive any treatment for reported events. The clinical outcome of the event loss of appetite was resolved on 25Mar2021 while the clinical outcome of the events fever of 103.8, left underarm lymph node swollen to the size of an egg, severe headache, joint pain, injection site swollen up to the size of hand and very fatigue was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pyrexia, Vaccination site swelling
Clinical narrative: Loss of appetite; Severe headache; Fever of 103.8; Left underarm lymph node swollen to the size of an egg; Joint pain; Injection site swell up to the sizeof my hand; Very fatigue; This is a spontaneous report received from a contactable consumer, the patient. A 53-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 22Mar2021 at 13:00 (at the age of 53-years-old) as a single dose, for COVID-19 immunisation. Medical history included asthma, high blood pressure, osteoarthritis and overweight. Concomitant medications included tiotropium bromide monohydrate (SPIRIVA RESPIMAT), budesonide, formoterol fumarate (SYMBICORT), meloxicam (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN); all for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 02Mar2021 at 15:00 (at the age of 53-year-old) as a single dose, for COVID-19 immunisation. The patient had a history of allergy to tree nuts. The patient did not receive any other vaccine in four weeks prior to COVID vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021 at 04:15, within 24 hours the patient had fever of 103.8 (unspecified units), left underarm lymph node swollen to the size of an egg, severe headache, joint pain, injection site swollen up to the size of hand, loss of appetite and had very fatigue. The patient reported that after 48 hours, body temperature went down to 101.6 (unspecified units) everything else the same. It was reported that on day 3, the body temperature of the patient had reduced to 100.5, appetite came back, still had some fatigue, joint pain reduced, lymph node still swollen and very painful, injection site still size of hand. The patient did not receive any treatment for reported events. The clinical outcome of the event loss of appetite was resolved on 25Mar2021 while the clinical outcome of the events fever of 103.8, left underarm lymph node swollen to the size of an egg, severe headache, joint pain, injection site swollen up to the size of hand and very fatigue was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Headache, Hypoaesthesia, Lip pain, Lip swelling
Clinical narrative: Numbness/tingling in fingers; Back pain; Numbness and tingling on side of face; headaches; lips feeling sore; lips feeling swollen; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6206) via an unspecified route of administration in the left arm on 11Mar2021 at 14:30 (at the age of 27-years-old), as a single dose for COVID-19 immunisation. Medical history was not available. The patient had BACTRIM allergy. Concomitant medication included womens daily gummy multi vitamin. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 11Mar2021 at 14:45, the patient experienced numbness or tingling in fingers immediately after vaccine. On an unknown date in Mar2021, the patient experienced numbness and tingling on side of face over past few weeks (mild) that was increasing but still had control of facial movement and also intermittent back pain but was still able to continue exercising routine most days. In week one, in Mar2021, the patient experienced headaches intermittently and week 2.5, she had lips feeling sore and swollen. The patient did not receive treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events numbness/tingling in fingers, back pain, numbness and tingling on side of face, headaches, lips feeling sore and lips feeling swollen was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous, Rash pruritic, Vaccination site reaction
Clinical narrative: Developed a red, itchy round patch about 2 inches in diameter; Delayed skin reaction at injection sitein upper left arm.; Developed a red, itchy round patch about 2 inches in diameter; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204) via an unspecified route of administration in the left arm on 18Mar2021 at 13:45 (at the age of 49-years-old), as single dose for COVID-19 immunisation. Medical history included hypertension (controlled with medication). The patient did not have any allergies to food, medications, or other products. Concomitant medications included calcium levomefolate; drospirenone; ethinylestradiol betadex clathrate (BEYAZ) and olmesartan (MANUFACTURER UNKNOWN), both for unspecified indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021, the patient experienced delayed skin reaction at injection site in upper left arm and developed a red, itchy round patch about 2 inches in diameter. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events vaccination site reaction, red rash and itchy rash was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia, Pyrexia
Clinical narrative: Fever; Chills; Headache; Some muscle soreness; This is a spontaneous report received from a non-contactable consumer, the patient. A 28-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: 3248) via unspecified route of administration in the left arm on 24Mar2021 at 11:30 (at the age of 28-years-old), as a single dose for COVID-19 immunisation. The patients medical history included seasonal allergies, depression, anxiety and asthma. The patient past drug history included known allergy to antibiotic such as cefaclor (CECLOR). The concomitant medications included sertraline hydrochloride (ZOLOFT) at a dose of 200mg/day taken for unknown indication from an unspecified date and budesonide; formoterol fumarate (SYMBICORT) taken for asthma since an unspecified date. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 25Mar2021 at 04:00, the patient experienced fever, chills, headache and some muscle soreness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the reported events. The clinical outcome of the events fever, chills, headache and muscle soreness was recovered on an unspecified date.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metal taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL9269) via an unspecified route of administration in the left arm on 18Mar2021 at 16:15 (at the age of 37 years old), as a single dose for COVID-19 immunisation. The patient had known allergies to lobsters and shrimps. The medical history of the patient and concomitant medications was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL9266) via an unspecified route of administration in the left arm on 25Feb2021 at 16:15 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021, the patient experienced metallic taste. No therapeutic measures were taken as a result of the events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event metallic taste was not recovered at the time reporting.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea
Clinical narrative: Nausea; Headache; Fatigue; This is a spontaneous report received from a contactable consumer, the patient. A 52-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6208), via unspecified route of administration in the right arm on 25Mar2021 at 13:15(at the age of 52-years-old) for COVID-19 immunisation. Medical history of the patient included ovarian cyst and there were no known allergies. The concomitant medications included medroxyprogesterone (MANUFACTURER UNKNOWN), vitamin D3 (MANUFACTURER UNKNOWN), vitamin c (MANUFACTURER UNKNOWN) and Zinc (MANUFACTURER UNKNOWN) all taken for unknown indications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 25Mar2021 at 20:00, the patient experienced headache and fatigue on evening of injection (8 hours after), continued headache and acute nausea on the following morning (26Mar2021). Mild headache and mild nausea continued 24 hrs after. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, fatigue and nausea was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Pyrexia
Clinical narrative: body ache; Fever; chills; fatigue; This is a spontaneous report from a contactable consumer. A 49-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 25Mar2021 at 10:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included amlodipine besilate (NORVASC) and cetirizine hydrochloride (ZYRTEC) for unknown indications from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 10:00, the patient experienced fever, chills, fatigue and body ache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, fatigue and body ache. The clinical outcomes of the events fever, chills, fatigue and body ache were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Fatigue, Headache, Nausea
Clinical narrative: Severe chills; shivering; body aches; headache; Weakness; fatigue; Nausea; This is a spontaneous report received from a non-contactable consumer, the patient. A 43-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 25Mar2021 at 13:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included thalassemia. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and ibuprofen (ADVIL); both from unknown date for unspecified indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 04Mar2021 at 13:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation and shrimp on unknown date and experienced an seafood allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 26Mar2021 at 02:00, the patient experienced severe chills, shivering, body aches, headache, weakness, fatigue and nausea. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the severe chills, shivering, body aches, headache, weakness, fatigue and nausea was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Severe chills; shivering; body aches; headache; Weakness; fatigue; Nausea; This is a spontaneous report received from a non-contactable consumer, the patient. A 43-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 25Mar2021 at 13:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included thalassemia. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and ibuprofen (ADVIL); both from unknown date for unspecified indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 04Mar2021 at 13:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation and shrimp on unknown date and experienced an seafood allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 26Mar2021 at 02:00, the patient experienced severe chills, shivering, body aches, headache, weakness, fatigue and nausea. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the severe chills, shivering, body aches, headache, weakness, fatigue and nausea was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Musculoskeletal stiffness, Tenderness
Clinical narrative: Dizziness,lightheadedness.; Muscle stiffness; Tiredness; tenderness in Left arm; This is a spontaneous report from a non-contactable consumer, the patient. A 66-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 24Mar2021 at 11:15 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9269) via an unspecified route of administration in the left arm on 27Feb2021 at 13:45 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications included as colonoscopy preparations and daily supplements (unspecified) (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 24Mar2021 (day 1), the patient experienced only tenderness in left arm. Then on 25Mar2021 (day 2), the patient experienced muscle stiffness, tiredness and began to feel dizzy and on 26Mar2021 (day 3), the patient experienced dizziness. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care The clinical outcome of the event tenderness, muscle stiffness, tiredness and dizziness were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Lymphadenopathy
Clinical narrative: Tiredness; headache; fever and temperature of 100.8; chills; swollen lymph nodes; muscle pain; This is a spontaneous report received from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8932) via unspecified route of administration in left arm on 23Mar2021 (at the age of 70-year-old) at 14:45 as a single dose for COVID-19 immunisation. Medical history of the patient was not reported. The patient also took other unspecified medications in two weeks. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The past drug history of the patient included the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN62600) via unspecified route of administration on an unspecified date in left arm for COVID-19 immunisation.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient experienced tiredness, headache, fever & chills, swollen lymph nodes, muscle pain, temperature 100.8(unspecified units) on 24Mar2021 at 04: 00. The patient did not receive any treatment for the events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of tiredness, headache, fever & chills, swollen lymph nodes, muscle pain, temperature 100.8(unspecified units) was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Tiredness; headache; fever and temperature of 100.8; chills; swollen lymph nodes; muscle pain; This is a spontaneous report received from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8932) via unspecified route of administration in left arm on 23Mar2021 (at the age of 70-year-old) at 14:45 as a single dose for COVID-19 immunisation. Medical history of the patient was not reported. The patient also took other unspecified medications in two weeks. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The past drug history of the patient included the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN62600) via unspecified route of administration on an unspecified date in left arm for COVID-19 immunisation.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient experienced tiredness, headache, fever & chills, swollen lymph nodes, muscle pain, temperature 100.8(unspecified units) on 24Mar2021 at 04: 00. The patient did not receive any treatment for the events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of tiredness, headache, fever & chills, swollen lymph nodes, muscle pain, temperature 100.8(unspecified units) was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Swelling, Urticaria
Clinical narrative: red welts on right side of my face; Itchy; slight swelling; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER2613) via an unspecified route of administration in the right arm on 23Mar2021 (at the age of 47-year-old) at 10:00 as a single dose for COVID-19 immunisation. Medical history included high blood pressure and diabetes. Concomitant medications included Pepcid (MANUFACTURER UNKNOWN), celexa (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNWON). The patient was allergic to codeine (MANUFACTURER UNKNOWN) and stadol (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 25Mar2021 at 08:00, the patient experienced itchy, red welts on the right side of the face and slight swelling. No treatment was taken taken for the reported events. The clinical outcome of the events itchy, red welts on right  side of the face and slight swelling were recovering at the time of report.   No follow-up attempts possible. No further information expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Vertigo
Clinical narrative: vertigo; headache; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via unspecified route of administration in the right arm on 22Mar2021 at 14:00 (at the age of 45-years-old) as a single dose for Covid-19 immunisation. The patients medical history was reported as none. The patient previously received codeine (MANUFACTURER UNKNOWN) for unspecified indication and experienced drug allergy. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 01Mar2021 at 14:00 as a single dose for COVID-19 immunisation The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since having the vaccine. On 26Mar2021 at 07:00, 4 days after second dose patient experienced severe headaches for several days and severe vertigo. The patient did not receive any treatment for the events headache and vertigo. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of headache and vertigo was not resolved at the time of report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia, Vaccination site pain
Clinical narrative: Low grade (99.9*) Fever; Injection Site pain; This is a spontaneous report from a non-contactable consumer, the patient. A 50-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3248); via unspecified route of administration in the left arm on 25Mar2021 (at the age 50-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955); via unspecified route of administration in the left arm on 04Mar2021 (at the age 50-years-old) as a single dose for COVID-19 immunisation. The patient did not have a history of allergies to medications, food, or other products. The patient did not receive any other vaccine within four weeks prior to vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 01:30, the patient had experienced low grade fever (99.9) and injection site pain. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of low-grade fever and injection site pain. The clinical outcome of the events low grade (99.9) fever and injection site pain was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Hyperhidrosis, Lethargy, Pain, Pyrexia
Clinical narrative: Fever 102.2; sweating, body aches, headache, lethargy; headache; body aches; sweating; lethargy; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8727) in the left arm on 25Mar2021 at 13:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient included osteoporosis, arthritis and cholesterol. Concomitant medications of the patient included rosuvastatin (MANUFACTURER UNKNOWN), citalopram (MANUFACTURER UNKNOWN), D3 (MANUFACTURER UNKNOWN), Magnesio (MANUFACTURER UNKNOWN), calcium (MANUFACTURER UNKNOWN) and CENTRUM all used for unknown indications from unknown dates within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6206) in the left arm on 04Mar2021 at 13:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. The patient had a known history of allergy to penicillin. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 26Mar2021 at 23:00, the patient experienced fever 102.2 (unit unspecified), sweating, body aches, headache and lethargy. Therapeutic measures were not taken as a result of all events. On 26Mar2021, the patient underwent a fever test and the result was 102.2. The clinical outcome of the events fever, sweating, body aches, headache and lethargy was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Micturition urgency, Pollakiuria, Viral test
Clinical narrative: Frequent urination days after receiving first dose vaccine; urgent urination days after receiving first dose vaccine.; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318), via an unspecified route of administration in left arm on 06Feb2021 at 10:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient was allergic to the drug benzole peroxide. Concomitant medications were not reported. The patient had not been diagnosed with COVID-19 prior to the vaccination. The patient underwent lab tests and procedures which included nasal swab test in Mar2021 and tested negative. The patient had also received a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in left arm in Mar2021 as a single dose for COVID-19 immunisation. On 10Feb2021, at 10:00 the patient had experienced frequent urination and urgent urination after receiving the first dose vaccine. No treatment was received for the adverse events. The clinical outcome of the events frequent urination and urgent urination was not recovered at the time of report. No follow-up attempts are possible; No further information is expected.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Headache, Poor quality sleep, Pyrexia
Clinical narrative: Headache; prevented me from sleeping restfully; 100.5 F fever; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204) via an unspecified route of administration in the left arm on 25Mar2021 at 13:45 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as not applicable. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9266) via an unspecified route of administration in the left arm on 04Feb2021 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, patient had not been tested for COVID-19. On 25Mar2021 at 23:45, the patient had headache in the evening that prevented from sleeping restfully. The patient woke up with fever of 100.5F. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache, sleep restless and fever was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.